stoxline Quote Chart Rank Option Currency Glossary
  
Accelerate Diagnostics, Inc. (AXDX)
1.2662  -0.004 (-0.3%)    02-06 11:45
Open: 1.3
High: 1.3588
Volume: 4,523
  
Pre. Close: 1.27
Low: 1.26
Market Cap: 32(M)
Technical analysis
2025-02-06 11:47:19 AM
Short term     
Mid term     
Targets 6-month :  1.63 1-year :  1.9
Resists First :  1.39 Second :  1.63
Pivot price 1.23
Supports First :  1.18 Second :  1.04
MAs MA(5) :  1.3 MA(20) :  1.21
MA(100) :  1.54 MA(250) :  1.33
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  69.5 D(3) :  73.3
RSI RSI(14): 52.8
52-week High :  2.08 Low :  0.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AXDX ] has closed below upper band by 34.2%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.34 - 1.35 1.35 - 1.36
Low: 1.18 - 1.19 1.19 - 1.2
Close: 1.26 - 1.27 1.27 - 1.28
Company Description

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Headline News

Wed, 05 Feb 2025
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World

Fri, 10 Jan 2025
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire

Thu, 07 Nov 2024
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results - PR Newswire

Thu, 07 Nov 2024
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges - TipRanks

Mon, 30 Sep 2024
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System - PR Newswire

Thu, 08 Aug 2024
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 25 (M)
Shares Float 12 (M)
Held by Insiders 40.5 (%)
Held by Institutions 17.4 (%)
Shares Short 473 (K)
Shares Short P.Month 468 (K)
Stock Financials
EPS -2.59
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.38
Profit Margin 0 %
Operating Margin -288.3 %
Return on Assets (ttm) -75.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 2.2 %
Gross Profit (p.s.) 0.08
Sales Per Share 0.48
EBITDA (p.s.) -1.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -32 (M)
Levered Free Cash Flow -55 (M)
Stock Valuations
PE Ratio -0.51
PEG Ratio 0
Price to Book value -0.95
Price to Sales 2.66
Price to Cash Flow -1.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android